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Abstract
Antimicrobial proteins and peptides (AMPs) are important effectors of the innate immune system that play a vital role in the
prevention of infections. Recent advances have highlighted the similarity between AMPs and amyloid proteins. Using the
Eosinophil Cationic Protein as a model, we have rationalized the structure-activity relationships between amyloid
aggregation and antimicrobial activity. Our results show how protein aggregation can induce bacteria agglutination and
cell death. Using confocal and total internal reflection fluorescence microscopy we have tracked the formation in situ of
protein amyloid-like aggregates at the bacteria surface and on membrane models. In both cases, fibrillar aggregates able to
bind to amyloid diagnostic dyes were detected. Additionally, a single point mutation (Ile13 to Ala) can suppress the protein
amyloid behavior, abolishing the agglutinating activity and impairing the antimicrobial action. The mutant is also defective
in triggering both leakage and lipid vesicle aggregation. We conclude that ECP aggregation at the bacterial surface is
essential for its cytotoxicity. Hence, we propose here a new prospective biological function for amyloid-like aggregates with
potential biological relevance.
Citation: Torrent M, Pulido D, Nogue´s MV, Boix E (2012) Exploring New Biological Functions of Amyloids: Bacteria Cell Agglutination Mediated by Host Protein
Aggregation. PLoS Pathog 8(11): e1003005. doi:10.1371/journal.ppat.1003005
Editor: H. Steven Seifert, Northwestern University Feinberg School of Medicine, United States of America
Received May 28, 2012; Accepted September 17, 2012; Published November 1, 2012
Copyright:  2012 Torrent et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: M.T. is a recipient of an Alianza Cuatro Universidades fellowship. D.P. is a recipient of a FPU fellowship (MICINN). Microscopy experiments were carried
at the Servei de Microsco`pia (UAB) and fluorescence measurements at Servei d’Ana`lisi i Fotodocumentacio´ (UAB). The work was funded by MICINN (BFU2009-
09371), FEDER funds and Generalitat de Catalunya (2009 SGR 795). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: marc.torrent@uab.cat (MT); ester.boix@uab.cat (EB)
Introduction
Antimicrobial proteins and peptides (AMPs) represent a wide
family that contributes to the host defense system with multiple
pathogen killing strategies [1–3]. Their fast and multitarget
mechanism of action reduces the emergence of bacteria resistance
and represents a valuable alternative for common antibiotics [4,5].
The mechanism of action of AMPs has been systematically
investigated, suggesting that AMPs bind to bacteria cell mem-
branes and disrupt cell homeostasis. However, more investigations
are needed to completely understand how different structures
determine the function of AMPs [6–12]. Membrane damage is a
multifaceted mechanism that can involve different peptide
assemblies and ultimately promotes membrane permeabilization
when achieving a critical concentration [13,14]. Several authors
have highlighted the striking resemblance of membrane disrupting
mechanisms with those observed for amyloid peptides and proteins
[15–17]. In both cases, membrane composition (e.g. cholesterol
content) and biophysical properties (e.g. membrane fluidity and
curvature) were found critical for the peptide action [13,15,18–
26]. Furthermore, we have recently suggested that antimicrobial
activity could have arisen through cationization of amyloid-prone
regions [27]. In this light, some AMPs have been described to form
amyloid structures in vitro [28,29] and some amyloid peptides have
also been considered as putative AMPs [30,31]. In fact, we have
proposed that inherent AMP aggregation properties can modulate
antimicrobial activity [32].
Interestingly, some antimicrobial proteins and peptides have
been found to agglutinate bacteria cells. In this sense, bacteria
agglutination has been ascribed to unspecific adhesion through
hydrophobic interactions, as observed for synthetic peptides
derived from the parotid secretory protein [33]. Comparative
analysis on those peptides highlighted the contributions of both
hydrophobic and cationic residues in the agglutination activity
[33]. These results suggest that some AMPs could exploit their
intrinsic aggregation properties, by triggering bacteria agglutina-
tion as part of its mechanism of action as observed for a wealth
source of AMPs in saliva, which provides a first barrier to bacteria
adherence in the oral cavity [34]. Agglutinating activity has been
reported crucial for the antimicrobial function of Eosinophil
Cationic Protein (ECP) [35], a small cationic protein specifically
secreted by eosinophil granules during inflammation processes
with diverse antipathogen activities [36–38]. ECP displays high
antimicrobial action, with a specific bacteria agglutination activity
reported for Gram-negative bacteria, at a concentration range
close to the minimal inhibitory concentration, a behavior that may
represent an effective bactericidal mechanism in vivo [39].
In order to characterize the relation between AMPs, bacteria
agglutination and amyloid aggregation, we have used ECP as a
model of study. We present here a detailed characterization of
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protein-mediated bacteria agglutination and prove the contribu-
tion of an aggregation prone domain to the protein antimicrobial
action. Complementary studies on model membranes provide a
further understanding of the membrane damage process promoted
by protein aggregation.
Results/Discussion
ECP was previously reported to aggregate in vivo on both
bacterial and eukaryotic cell surface without detectable internal-
ization [39,40]. Though these findings were essential to explain the
antimicrobial and cytotoxic properties of ECP, the real nature of
the aggregation process remained unknown. Besides, the protein
has a high affinity towards lipopolysaccharides (LPS) [41] and
agglutinates all tested Gram-negative strains [42]. On the other
hand, ECP has been reported to form amyloid-like aggregates in
vitro at specific conditions due to a hydrophobic patch located at
the N-terminus. Remarkably, protein amyloid-like aggregation
was efficiently abolished by mutating Ile 13 to Ala [28]. The
screening of the protein primary structure [43–45] and the design
of derived peptides [42,46] also allocated the antimicrobial region
at the N-terminus. As the antimicrobial and amyloid active
segments of the protein colocalize [28,35,42,46], it is tempting to
hypothesize that bacteria agglutination by ECP could be directly
dependent on an amyloid-like aggregation process. This hypoth-
esis raises some exciting questions: (i) Is cell agglutination required
for antimicrobial activity? (ii) Is cell agglutination mediated by
protein aggregation at the bacteria surface? (iii) Are aggregates
formed on the surface of bacteria of amyloid nature?
Bacteria cell agglutination and antimicrobial activities
To address the first question we compared the antimicrobial
action of wild type ECP (wtECP) with the I13A mutant, previously
described to be unable to form aggregates in vitro [28]. The
antimicrobial assays reveal that, while wtECP has an average
minimal inhibitory concentration (MIC) value around 0.5–1 mM,
the I13A mutant is unable to kill bacteria even at 5 mM
concentration (Table 1). To further correlate ECP antimicrobial
and agglutination activities we studied bacteria cell cultures by
confocal microscopy using the SYTO9/Propidium iodide nucleic
acid fluorescent labels that allow registering both cell agglutination
and viability over time. Interestingly, wtECP can agglutinate
Gram-negative bacteria before a viability decrease is observed
(Figure 1A), however no cell agglutination takes place when
bacteria are incubated with the I13A variant, even after 4 hours
(Supporting Information Figure S1). These results are also
supported by minimal agglutination concentrations (MAC) close
to the MIC values (Table 1) and by FACS experiments showing
that wtECP but not I13A mutant is able to agglutinate E. coli cells
(Figure 1B). Thus, ECP antimicrobial activity on Gram-negative
strains is strongly affected when abolishing the agglutination
behavior (Ile13 to Ala mutation).
Protein aggregation on membrane models
To further analyze the protein agglutination mechanism, we
tested the wtECP and I13A mutant action on a simpler biophysical
system such as phospholipid membranes where liposome agglu-
tination is registered as a function of protein concentration. In
contrast to wtECP, I13A mutant completely looses the ability to
agglutinate membranes (Figure 2A). In particular, when following
wtECP agglutinating activity as a function of ionic strength, we
observe that liposome agglutination is enhanced at high NaCl
concentration (Supporting Information, Figure S2). These results
suggest that vesicle agglutination is promoted by hydrophobic
interactions. Even more, leakage activity in model membranes is
also lost for I13A mutant (Figure 2B), meaning that protein
aggregation on the membrane surface is important not only for
agglutination but also for later membrane permeabilization. These
results are entirely consistent with those described above for
bacteria cell cultures where the Ile to Ala mutation not only
Author Summary
Microbial infections are reported among the worst human
diseases and cause millions of deaths per year over the
world. Antibiotics are used to treat infections and have
saved more lives than any other drug in human history.
However, due to extended use, many strains are becoming
refractive to common antibiotics. In this light, new
promising compounds, like antimicrobial proteins and
peptides (AMPs) are being investigated. Some AMPs also
show agglutinating activity; this is the ability to clump
bacteria after treatment. This feature is particularly
appealing because agglutinating peptides could be used
to keep bacteria to the infection focus, helping microbe
clearance by host immune cells. In this study, we propose
a novel mechanism to explain agglutinating activity at a
molecular level using Eosinophil Cationic Protein. We show
that the agglutinating mechanism is driven by the protein
amyloid-like aggregation at the bacteria cell surface.
Accordingly, elimination of the amyloid behavior abolishes
both the agglutinating and the antimicrobial activities.
This study provides a new concept on how Nature could
exploit amyloid-like aggregates to fight bacterial infec-
tions. Moreover, these results could also add new insights
in understanding the relation between infection and
inflammation with dementia and amyloid-related diseases
like Alzheimer.
Table 1. Antimicrobial (MIC100) and agglutinating (MAC) activities of wtECP and I13A mutant in Gram-negative strains.
MIC100 (mM) MIC100 (mM) MAC (mM) MAC (mM)
Phosphate buffera MH mediumb Phosphate buffera MH mediumb
ECP I13A ECP I13A ECP I13A ECP I13A
E. coli 0.4060.10 .5 0.4560.10 .5 0.2560.1 .5 0.2560.1 .5
P. aeruginosa 0.6060.15 .5 0.9060.20 .5 0.560.1 .5 0.560.1 .5
A. baumanii 0.7560.15 .5 1.2560.20 .5 1.060.2 .5 1.060.2 .5
aBacteria were grown in LB medium and incubated with proteins in 10 mM NaH2PO4, 100 mM NaCl pH 7.4.
bBacteria were grown and incubated with proteins in Mueller–Hinton II broth.
doi:10.1371/journal.ppat.1003005.t001
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abolishes the cell agglutinating activity of ECP but also its
bactericidal action.
Agglutination mediated by protein aggregation
Next, to address the question whether cell agglutination is
consistently driven by protein aggregation at the bacteria surface,
we incubated bacteria cultures with ECP and visualized the
samples using confocal microscopy. Our results show that wtECP
binds to the bacteria surface and a strong protein signal is
registered at the aggregation zones (Figure 3A). On the contrary,
though cell interaction is maintained for the I13A mutant,
agglutination is observed neither in bacteria cell cultures nor in
model membranes (Figures 3A and 3B). As expected, for model
membranes we show that only wtECP is able to promote
agglutination (Figure 3B). Therefore, we conclude that protein
aggregation on the cellular surface is required for bacteria
agglutination, which turns to be essential for the antimicrobial
action. Agglutination is also observed in the presence of 20%
plasma in a similar extent, suggesting that ECP agglutination is
likely to take place in the physiological context (Supplementary
Information Figure S3). As previously mentioned, ECP binding to
bacteria is favored by interactions with the LPS outer membrane
[35,41,47]. Consistently, we show here that LPS binding activity is
lost for the I13A mutant, when compared with wtECP (Supple-
mentary Information Figure S4).
In situ follow-up of amyloid aggregates
At this point however, the nature of the protein aggregates
remained unknown. Thus, having previously shown that ECP is
able to form amyloid-like aggregates in vitro, we decided to test if
the observed aggregates have an amyloid-like structure using the
amyloid-diagnostic dyes Thioflavin-T and Congo Red. When
bacteria cultures are incubated with non-labeled wtECP, stained
with ThT and visualized by total internal reflection fluorescence
(TIRF) microscopy, we show that wtECP amyloid-like aggregates
are located also at the cell surface (Figure 4A) similarly as what we
observe for Alexa labeled wtECP (Figure 3A). Consistently, no
staining is observed for non-incubated cultures and for the I13A
mutant (Figure 4A). Moreover, upon bacteria incubation with
wtECP, a red shift in the Congo Red spectrum is observed
(Supplementary Information Figure S5A), revealing that the
protein amyloid-like aggregation is triggered upon incubation
with bacteria cultures.
Though ECP was previously shown to form amyloid-like
aggregates in vitro only at low pH after a long incubation time
(1–2 weeks), amyloid-like structures observed here are detected
after only 4 hours of incubation. However, it is well known that
some proteins can accelerate its aggregation kinetics in the
presence of membrane-like environments [48–50]. Our results
show that wtECP is able to form fibrillar-like aggregates on model
membranes with an average size of 8456150 nm (Figure 4B),
comparable in size with the wtECP aggregates observed in vitro in
the absence of lipid membranes (,150 nm) [28]. In fact, when
tested for ThT binding, we observe aggregates with similar size
(Figure 4B). When wtECP is incubated with model membranes
and tested for Congo Red binding, we obtain again a noticeable
spectral shift (Supplementary Information Figure S5B). To
complete these results we have also performed all the experiments
detailed above using the I13A mutant and found it to be unable to
form amyloid-like aggregates (Figure 4).
Conclusions
The results presented here for ECP reinforce the hypothesis that
an amyloid-like aggregation process is taking place in the bacteria
surface that drives bacteria cell agglutination, which is essential for
the antimicrobial activity of the protein. In summary, after binding
to the bacteria surface, a rearrangement of the protein could take
place, exposing the hydrophobic N-terminal patch of the protein.
Following, the aggregation process would start promoting the
agglutination of the bacteria cells through the aggregation of the
surface-attached protein molecules. The formation of aggregates
on the bacteria surface will disrupt the lipopolysaccharide bilayer
of Gram-negative cells exposing the internal cytoplasmatic
membrane to the protein action, promoting the membrane
disruption and eventually the bacteria killing.
Cell agglutinating activity provides a particularly appealing
feature that may contribute to the clearance of bacteria at the
infectious focus. In this sense, bacteria agglutination would
prepare the field before host phagocytic cells enter in the scene
[33]. However, despite the interest in the pharmaceutical industry
to identify the structural determinants for bacteria cell agglutina-
tion, bibliography on that subject is scarce and only few
agglutinating antimicrobial proteins are described in the literature.
Excitingly, there may be other proteins and peptides with similar
characteristics that also follow the proposed model. Hence, the
agglutinating mechanism may represent a more generalized
process that may derivate in amyloid deposit formation at
bacterial infection focuses.
Besides, it has been reported that systematic exposure to
inflammation may represent a risk factor on developing Alzhei-
mer’s disease [51,52] and other types of dementia [53]. Some
studies have also demonstrated that the release of inflammatory
mediators can also cause generalized cytotoxicity. In particular,
ECP has been discovered to be cytotoxic [40,54] and neurotoxic,
causing the Gordon phenomenon after injection intratechally in
rabbits [55]. Therefore, our results suggest that the release of
inflammatory mediators after infection (like AMPs) may either
seed the aggregation processes in the brain and/or influence the
membrane biophysical properties to trigger neurotoxicity and
aggregation events.
Materials and Methods
MIC (Minimal Inhibitory Concentration) and MAC
(Minimal Agglutination Concentration) determination
Antimicrobial activity was expressed as the MIC100, defined as
the lowest protein concentration that completely inhibits microbial
growth. MIC of each protein was determined from two
Figure 1. ECP but not I13A is able to agglutinate bacteria. (A) E. coli, P. aeruginosa and A. baumanii cells were incubated with 5 mM of ECP or
I13A mutant in microscopy plates during 4 h and stained with syto9 (live cells, green) and propidium iodide (dead cells, red). Images were taken at 0,
0.5 and 3 h using a Leica SP2 confocal microscopy as described in the Materials and Methods section. Scale bar represents 50 mm. Arrows were
depicted to show cell agglutination. Images depicted are representative from two independent experiments. (B) E. coli cells were incubated with
5 mM of ECP or I13A mutant during 4 h and samples were analyzed using a FACSCalibur cytometer. FSC-H is the low-angle forward scattering, which
is roughly proportional to the diameter of the cell and SSC-H is the orthogonal or side scattering, which is proportional to cell granularity or
complexity. Agglutination is registered as an increase in both scattering measures. In all experiments cell cultures were grown at exponential phase
(OD600 = 0.2) and incubated with proteins in 10 mM sodium phosphate buffer, 100 mM NaCl, pH 7.4. The plots are representative of three
independent experiments.
doi:10.1371/journal.ppat.1003005.g001
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independent experiments performed in triplicate for each concen-
tration. Bacteria were incubated at 37uC overnight in Mueller-
Hinton II (MHII) broth and diluted to give approximately
5?105 CFU/mL. Bacterial suspension was incubated with proteins
at various concentrations (0.1–5 mM) at 37uC for 4 h either in
MHII or 10 mM sodium phosphate buffer, 100 mM NaCl,
pH 7.4. Samples were plated onto Petri dishes and incubated at
37uC overnight.
For MAC determination, bacteria cells were grown at 37uC to
mid-exponential phase (OD600 = 0.6), centrifuged at 50006g for
2 min, and resuspended in 10 mM sodium phosphate buffer,
100 mM NaCl, pH 7.4, in order to give an absorbance of 0.2 at
600 nm. A 200 mL aliquot of the bacterial suspension was
incubated with proteins at various (0.1–10 mM) concentrations at
25uC for 4 h. Aggregation behavior was observed by visual
inspection and minimal agglutinating concentration expressed as
previously described [42].
Fluorescence-Assisted Cell Sorting (FACS) assay
Bacteria cells were grown at 37uC to mid-exponential phase
(OD600 = 0.6), centrifuged at 50006g for 2 min, resuspended in
10 mM sodium phosphate buffer, 100 mM NaCl, pH 7.4 or the
same buffer supplemented with 20% plasma to give a final
OD600 = 0.2 and preincubated for 20 min. A 500 mL aliquot of the
bacterial suspension was incubated with 5 mM of wtECP or I13A
mutant during 4 h. After incubation, 25000 cells were subjected to
FACS analysis using a FACSCalibur cytometer (BD Biosciences,
New Jersey) and a dot-plot was generated by representing the low-
angle forward scattering (FSC-H) in the x-axis and the side
scattering (SSC-H) in the y-axis to analyze the size and complexity
of the cell cultures. Results were analyzed using FlowJo (Tree Star,
Ashland, OR).
Figure 2. Liposome agglutination and leakage activity. wtECP
(circles) and I13A mutant (squares) were incubated with liposomes and
the agglutination (A) and leakage (B) were followed at increasing
protein concentrations (1–6 mM). Agglutination was measured as light
scattering (470 nm) at 90u from the beam source in a 10 mM Tris-HCl,
100 mM NaCl, pH 7.4 buffer and leakage was followed using the ANTS/
DPX assay in the same buffer as described in the Materials and Methods
section.
doi:10.1371/journal.ppat.1003005.g002
Figure 3. ECP and I13A mutant bind to the surface of bacteria
and membranes. (A) E. coli bacteria cells stained with Hoechst (blue
signal) were incubated with 5 mM of either wtECP or I13A mutant (both
labeled with Alexa Fluor 488; green signal) for 4 h and visualized by
confocal microscopy. In all experiments cell cultures were grown at
exponential phase (OD600 = 0.2) and incubated with proteins in 10 mM
sodium phosphate buffer, 100 mM NaCl, pH 7.4. (B) 500 ml of 200 mM
LUV liposomes stained with DiI (red signal) were incubated with 5 mM
of either wtECP or I13A mutant (both labeled with Alexa Fluor 488;
green signal) for 4 h and visualized using a Leica SP2 confocal
microscope. Scale bars are 5 mm length in all images and insight
captions. Images depicted are representative from two independent
experiments.
doi:10.1371/journal.ppat.1003005.g003
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Bacteria viability assay
Bacteria viability assays were performed as described before [39].
Briefly, bacteria were incubated in 10 mM sodium phosphate buffer,
100 mM NaCl, pH 7.4 with 5 mM of wtECP or I13A mutant and
then stained using a syto 9/propidium iodide 1:1 mixture. The
viability kinetics were monitored using a Cary Eclipse Spectrofluo-
rimeter (Varian Inc., Palo Alto, CA, USA). To calculate bacterial
viability, the signal in the range 510–540 nm was integrated to obtain
the syto 9 signal (live bacteria) and from 620–650 nm to obtain the
propidium iodide signal (dead bacteria). Then, the percentage of live
bacteria was represented as a function of time.
Liposome agglutination and leakage assay
The ANTS/DPX liposome leakage fluorescence assay was
performed as previously described [56]. Briefly, a unique population
of LUVs of DOPC/DOPG (3:2 molar ratio) lipids was obtained
containing 12.5 mM ANTS, 45 mM DPX, 20 mM NaCl, and
10 mM Tris/HCl, pH 7.4. The ANTS/DPX liposome suspension
was diluted to 30 mM concentration and incubated at 25uC in the
presence of wtECP or I13A mutant. Leakage activity was followed
by monitoring the increase of the fluorescence at 535 nm.
For liposome agglutination, 200 mM LUV liposomes were
incubated in 10 mM phosphate buffer, pH 7.4, containing 5 to
100 mM NaCl, in the presence of 5 mM wtECP or I13A mutant
and the scattering signal at 470 nm was collected at 90u from the
beam source using a Cary Eclipse Spectrofluorimeter (Varian Inc.,
Palo Alto, CA, USA) [57].
Confocal microscopy
Experiments were carried out in 35 cm2 plates with a glass
coverslip. For phospholipid membranes, 500 ml of 200 mM LUV
liposomes (prepared as described in Supplementary Information)
were incubated with 5 mM wtECP or I13A mutant for 4 h in
10 mM sodium phosphate buffer, 100 mM NaCl, pH 7.4. For
bacteria, 500 ml of E. coli cells (OD600= 0.2) were incubated with
5 mM wtECP or I13A mutant for 4 h in 10 mM sodium phosphate
buffer, 100 mM NaCl, pH 7.4. RNase A was used always as a
negative control. Samples of both liposomes and bacteria were
imaged using a laser scanning confocal microscope (Olympus
FluoView 1000 equipped with a UPlansApo 606objective in 1.4 oil
immersion objective, United Kingdom). wtECP and I13A mutant
labeled with Alexa Fluor 488 were excited using a 488-nm argon
laser (515–540 nm emission collected) and Vibrant DiI was excited
using an orange diode (588–715 nm emission collected).
TIRF microscopy
To study the interaction of proteins with lipid membranes,
planar supported lipid bilayers were used (Supplementary
Figure 4. ECP but not I13A form amyloid-like aggregates on the surface of bacteria and membranes. (A) E. coli bacteria cells stained
with Hoechst (blue signal) were incubated with unlabeled wtECP or I13A mutant for 4 h, stained with ThT (green signal) and visualized by TIRF
microscopy. In all experiments cell cultures were grown at exponential phase (OD600 = 0.2) and incubated with proteins in 10 mM sodium phosphate
buffer, 100 mM NaCl, pH 7.4. (B) Planar lipid bilayers prepared as described in the Materials and Methods section (stained with DiI; red signal) were
incubated with 5 mM of either unlabeled wtECP or I13A mutant for 4 h, stained with 25 mM ThT (green signal) and visualized using a Olympus
FluoView 1000 TIRF microscope. Scale bar represents 20 mm (5 mm in the insight caption). Images depicted are representative from two independent
experiments.
doi:10.1371/journal.ppat.1003005.g004
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Information). When using bacteria, glass coverslips were previ-
ously treated with 0.1% poly-L-lysine to ensure that samples will
adhere to the surface. 500 ml of E. coli cells (OD600 = 0.2) were
incubated with 5 mM wtECP or I13A mutant for 4 h and then
transferred to poly-L-lysine treated microscopy plates and
incubated for 15 minutes. To remove unattached cells, plates
were washed twice with 10 mM sodium phosphate, 100 mM
NaCl, pH 7.4 buffer. RNase A was used always as a negative
control. Images were captured using a laser scanning confocal
microscope (Olympus FluoView 1000 equipped with a PlansApo
606 TIRF objective in 1.4 oil immersion objective, United
Kingdom) using the same conditions as described for confocal
microscopy experiments. Thioflavin T (ThT) was used to detect
amyloid aggregates. In this case, samples were incubated for 4 h
with unlabeled proteins as described before and then incubated
with ThT at 25 mM final concentration for 15 minutes. Then,
plates were washed twice with 10 mM sodium phosphate,
100 mM NaCl buffer, pH 7.4 to remove unattached cells and
ThT excess.
Supporting Information
Figure S1 Bacteria agglutination mediated by wtECP
and the I13A mutant. E. coli bacteria cells were grown at
exponential phase (OD600 = 0.2) and incubated with 0.5 mM
wtECP (A) or I13A (B) in 10 mM phosphate buffer, 100 mM
NaCl, pH 7.5 for 4 h. Images were taken using a Leica
magnificator. wtECP incubated bacteria samples were also
observed under 406 (C) and 1006 (D) magnification to reveal
more details on bacteria aggregates. Images were taken using a
Leica optical microscope.
(TIF)
Figure S2 Liposome agglutination mediated by wtECP
and I13A mutant at increasing ionic strength. Liposomes
prepared as described in the Materials and Methods section were
incubated with increasing concentrations of wtECP (circles) or
I13A mutant (squares) at 5 mM (A), 50 mM (B) and 100 mM (C)
NaCl in a 10 mM phosphate buffer, pH 7.5. The formation of
liposome aggregates was followed as an increase in the light
scattering signal at 90u from the beam.
(TIF)
Figure S3 ECP is able to agglutinate bacteria cells in
plasma. E. coli cells were incubated with 5 mM of ECP during
4 h and samples were analyzed using a FACSCalibur cytometer.
FSC-H is the low-angle forward scattering, which is roughly
proportional to the diameter of the cell and SSC-H is the
orthogonal or side scattering, which is proportional to cell
granularity or complexity. Agglutination is registered as an
increase in both scattering measures. In all experiments, cell
cultures were grown at exponential phase (OD600 = 0.2) and
incubated with proteins in 20% plasma diluted in 10 mM sodium
phosphate buffer, 100 mM NaCl, pH 7.5. The plots are
representative of three independent experiments.
(TIF)
Figure S4 wtECP and I13A mutant binding to bacteria
LPS. LPS were incubated with increasing concentrations of
wtECP (circles) or I13A mutant (squares) in a 10 mM phosphate
buffer, 100 mM NaCl, pH 7.5. Binding to bacteria LPS was
registered as a fluorescence increase of the BODIPY-cadaverine
reporter as described in the Materials and Methods section. The
occupancy factor denotes the decrease of the LPS-bound dye
fraction after protein addition.
(TIF)
Figure S5 Protein aggregates bind to Congo Red dye. (A)
E. coli (circles) and P. aeruginosa (triangles) bacteria cells were
incubated 4 h with wtECP and assayed for Congo Red binding as
described in the Materials and Methods section. (B) Liposomes at
10 mM (black circles), 200 mM (grey circles) and 1 mM (white
squares) lipid concentration were incubated with wtECP and
assayed for Congo Red binding as described in the Materials and
Methods section. Congo Red differential spectra were obtained by
subtracting both the signal corresponding to the protein and the
lipid/bacteria in the presence of the dye. The vertical line at
480 nm represents the spectrum of Congo Red alone. Incubation
of I13A mutant with both bacteria and membranes did not display
any significant spectral shift.
(TIF)
Protocol S1 This file contains additional details for the
Materials and Methods section.
(DOCX)
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